Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma

Cancer Control

Volumn 11, Issue 3, 2004, Pages 174-180

  Sampath, Prakash ^a   Weaver, Charles E ^a   Sungarian, Arno ^a   Cortez, Selina ^a   Alderson, Lloyd ^a   Stopa, Edward G ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOVERIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; BLOOD LEVEL; BRAIN CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PARANEOPLASTIC SYNDROME; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECURRENT CANCER; RETINOPATHY; REVIEW; SERODIAGNOSIS; TUMOR DIAGNOSIS;

EID: 2942556808     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480401100305     Document Type: Review

References (27)

1. Cancer Facts & Figures, 2004. Atlanta, Ga: American Cancer Society, Inc; 2004.
2. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol. 2001;55:195-204.
3. Mukasa A, Ueki K, Matsumoto S, et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene. 2002;21:3961-3968.
4. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48:825-830.
5. Hashimoto N, Murakami M, Takahashi Y, et al. Correlation between genetic alteration and long-term outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer. 2003;97:2254-2261.
6. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet. 2003;361:1122-1128.
7. Caty A, Gosselin P, Cazin JL, et al. Significance of PSA and PAP in patients with or without prostatic cancer. Am J Clin Oncol. 1988;11(suppl 2):S63-S64.
8. Thompson DMP, Krupey J, Freedman SO, et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA. 1969;64:161-167.
9. Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am. 2003;30:263-277.
10. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol. 1998;49:189-196.
11. Chan AS, Leung SY, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol. 1998;22:816-826.
12. Chaudhry IH, O'Donovan DG, Brenchley PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 2001;39:409-415.
13. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol. 1994;4:207-218.
14. Zagzag D. Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol. 1995;146:293-309.
15. Strugar J, Rothbart D, Harrington W, et al. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg. 1994;81:560-566.
16. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia. 1995;15:339-347.
17. Weindel K, Moringlane JR, Marme D, et al. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery. 1994;35:439-449.
18. Stockhammer G, Obwegeser A, Kostron H, et al. Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol (Berl). 2000;100:101-105.
19. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest. 1993;91:153-159.
20. Abdulrauf SI, Edvardsen K, Ho KL, et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg. 1998;88:513-520.
21. Yao Y, Kubota T, Sato K, et al. Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir (Wien). 2001;143:159-166.
22. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996;56:2185-2190.
23. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology. 2000;54:1670-1676.
24. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol. 1987;105:372-375.
25. Dizhoor AM, Ray S, Kumar S, et al. Recoverin: a calcium sensitive activator of retinal rod guanylate cyclase. Science. 1991;251:915-918.
26. Goldstein SM, Syed NA, Milam AH, et al. Cancer-associated retinopathy. Arch Ophthalmol. 1999;117:1641-1645.
27. Prat M, Medico E, Piantino P, et al. The monoclonal antibody-defined CAR-3 antigen is a serological marker associated with pancreatic carcinoma. Int J Biol Markers. 1988;3:29-35.